New tetromycin derivatives with anti-trypanosomal and protease inhibitory activities

Marine Drugs

Volumn 9, Issue 10, 2011, Pages 1682-1697

  Pimentel Elardo, Sheila M ^a,e   Buback, Verena ^b   Gulder, Tobias A M ^c,f   Bugni, Tim S ^d,g   Reppart, Jason ^d   Bringmann, Gerhard ^c   Ireland, Chris M ^d   Schirmeister, Tanja ^b,h   Hentschel, Ute ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Institute for Pharmacy and Food Chemistry   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF UTAH   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF BONN   (Germany)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Anti trypanosomal; Marine sponge; Protease inhibition; Streptomyces axinellae; Tetromycin

Indexed keywords

3C LIKE PROTEASE; ANTITRYPANOSOMAL AGENT; CATHEPSIN B; CATHEPSIN L; CYSTEINE PROTEINASE; FALCIPAIN; PAPAIN LIKE PROTEASE; RHODESAIN; TETROMYCIN B; TETROMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTIPARASITIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG STRUCTURE; ENZYME INHIBITION; IC 50; LEISHMANIA MAJOR; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SARS CORONAVIRUS; STREPTOMYCES; STREPTOMYCES AXINELLAE; TRYPANOSOMA BRUCEI;

AXINELLA POLYPOIDES; LEISHMANIA MAJOR; SARS CORONAVIRUS; STREPTOMYCES; TRYPANOSOMA BRUCEI;

EID: 80054894140     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md9101682     Document Type: Article

References (21)

1. Peiris, J.S.; Yuen, K.Y.; Osterhaus, A.D.; Stohr, K. The severe acute respiratory syndrome. N. Engl. J. Med. 2003, 349, 243-2441.
2. Fear, G.; Komarnytsky, S.; Raskin, I. Protease inhibitors and their peptidomimetic derivatives as potential drugs. Pharmacol. Ther. 2007, 113, 354-368. (Pubitemid 46149049)
3. pro) structure: Basis for design of anti-SARS drugs. Science 2003, 300, 1763-1767.
4. Laport, M.S.; Santos, O.S.; Muricy, G. Marine sponges: Potential sources of new antimicrobial drugs. Curr. Pharm. Biotechnol. 2009, 10, 86-105.
5. Scheuermayer, M.; Pimentel-Elardo, S.; Fieseler, L.; Grozdanov, L.; Hentschel, U. Microorganisms of Sponges: Phylogenetic Diversity and Biotechnological Potential. In Frontiers in Marine Biotechnology; Proksch, P., Müller, W.E.G., Eds.; Horizon Bioscience: Norwich, UK, 2006; pp. 289-312.
6. Thomas, T.R.A.; Kavlekar, D.P.; LokaBharathi, A. Marine drugs from sponge-microbe association - A review. Mar. Drugs 2010, 8, 1417-1468.
7. Fenical, W. Marine pharmaceuticals: Past, present and future. Oceanography 2006, 19, 110-119.
8. Lam, K.S. Discovery of novel metabolites from marine actinomycetes. Curr. Opin. Microbiol. 2006, 9, 245-251. (Pubitemid 43817620)
9. Bull, A.T.; Stach, J.E. Marine actinobacteria: New opportunities for natural product search and discovery. Trends Microbiol. 2007, 15, 491-499. (Pubitemid 350102189)
10. Pimentel-Elardo, S.M.; Scheuermayer, M.; Kozytska, S.; Hentschel, U. Streptomyces axinellae sp. nov., isolated from the Mediterranean sponge Axinella polypoides (Porifera). Int. J. Syst. Evol. Microbiol. 2009, 59, 1433-1437.
11. Hobbs, G.; Frazer, C.M.; Gardner, D.C.J.; Cullum, J.A.; Oliver, S.G. Dispersed growth of Streptomyces in liquid culture. Appl. Microbiol. Biotechnol. 1989, 31, 272-277. (Pubitemid 19191611)
12. Takeuchi, T.; Hamada, M.; Osanawa, H.; Takahashi, Y.; Sawa, R. Tetromycin A and B manufacture with Streptomyces. Japanese Patent JP 08165286, April 1996.
13. Takeuchi, T.; Hamada, M.; Nanagawa, H.; Takahashi, Y.; Sawa, R. Antibiotic tetromycin C1, C2, C3, C4 and C5 and their production. Japanese Patent JP 96-216484, March 1998.
14. Ponte-Sucre, A.; Vicik, R.; Schultheis, M.; Schirmeister, T.; Moll, H. Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity. Antimicrob. Agents Chemother. 2006, 50, 2439-2447. (Pubitemid 43993184)
15. Huber, W.; Koella, J.C. A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop. 1993, 55, 257-261.
16. Vicik, R.; Busemann, M.; Gelhaus, C.; Stiefl, N.; Scheiber, J.; Schmitz, W.; Schulz, F.; Mladenovic, M.; Engels, B.; Leippe, M.; Baumann, K.; Schirmeister, T. Aziridide-based inhibitors of cathepsin L: Synthesis, inhibition activity, and docking studies. Chem. Med. Chem. 2006, 1, 1126-1141. (Pubitemid 44622252)
17. Vicik, R.; Hoerr, V.; Glaser, M.; Schultheis, M.; Hansell, E.; McKerrow, J.K.; Holzgrabe, U.; Caffrey, C.R.; Ponte-Sucre, A.; Moll, H.; Stich, A.; Schirmeister, T. Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents. Bioorg Med. Chem. Lett. 2006, 16, 2753-2757.
18. Breuning, A.; Degel, B.; Schulz, F.; Buchold, C.; Stempka, M.; Machon, U.; Heppner, S.; Gelhaus, C.; Leippe, M.; Leyh, M.; et al. Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids. J. Med. Chem. 2010, 53, 1951-1963.
19. Ehmke, V.; Heindl, C.; Rottmann, M.; Freymond, C.; Schweizer, W.B.; Brun, R.; Stich, A.; Schirmeister, T.; Diederich, F. Potent and selective inhibition of cysteine proteases from Plasmodium falciparum and Trypanosoma brucei. ChemMedChem 2011, 6, 273-278.
20. Cheng, Y.; Prusoff, W.H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor, which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
21. Ludewig, S.; Kossner, M.; Schiller, M.; Baumann, T.; Schirmeister, T. Enzyme kinetics and hit validation in fluorometric protease assays. Curr. Top. Med. Chem. 2010, 10, 368-382.